Testing a new cancer treatment that targets TGFβ
Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer
This study is exploring a new way to treat cancer by using a special therapy that targets a specific pathway in tumors, and it's designed for patients whose tumors show signs of this pathway, aiming to make treatment more effective for a wider variety of cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11040515 on NIH RePORTER |
What this research studies
This research investigates a novel approach to cancer treatment using radiopharmaceutical therapy (RPT) that targets the transforming growth factor beta (TGFβ) pathway. By utilizing advanced imaging techniques, patients will be selected based on the presence of TGFβ activation in their tumors, allowing for a more personalized treatment strategy. The study aims to combine a neutralizing antibody against TGFβ with therapeutic isotopes to enhance the effectiveness of cancer treatment. This approach could potentially expand the use of RPT to a broader range of cancers beyond those currently treated with this method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast, brain, or lung cancers that exhibit TGFβ activation.
Not a fit: Patients with cancers that do not express TGFβ or those who are not eligible for radiopharmaceutical therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, targeted treatment option for various types of cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results with targeted radiopharmaceutical therapies in other cancer types, suggesting potential for success with this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Barcellos-Hoff, Mary Helen — University of California, San Francisco
- Study coordinator: Barcellos-Hoff, Mary Helen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.